Molecular regulation of cardiac hypertrophy.
INT J BIOCHEM CELL B
2023 - 2039.
Heart failure is one of the leading causes of mortality in the western world and encompasses a wide spectrum of cardiac pathologies. When the heart experiences extended periods of elevated workload, it undergoes hypertrophic enlargement in response to the increased demand. Cardiovascular disease, such as that caused by myocardial infarction, obesity or drug abuse promotes cardiac myocyte hypertrophy and subsequent heart failure. A number of signalling modulators in the vasculature milieu are known to regulate heart mass including those that influence gene expression, apoptosis, cytokine release and growth factor signalling. Recent evidence using genetic and cellular models of cardiac hypertrophy suggests that pathological hypertrophy can be prevented or reversed and has promoted an enormous drive in drug discovery research aiming to identify novel and specific regulators of hypertrophy. In this review we describe the molecular characteristics of cardiac hypertrophy such as the aberrant re-expression of the fetal gene program. We discuss the various molecular pathways responsible for the co-ordinated control of the hypertrophic program including: natriuretic peptides, the adrenergic system, adhesion and cytoskeletal proteins, IL-6 cytokine family, MEK-ERK1/2 signalling, histone acetylation, calcium-mediated modulation and the exciting recent discovery of the role of microRNAs in controlling cardiac hypertrophy. Characterisation of the signalling pathways leading to cardiac hypertrophy has led to a wealth of knowledge about this condition both physiological and pathological. The challenge will be translating this knowledge into potential pharmacological therapies for the treatment of cardiac pathologies. (C) 2008 Elsevier Ltd. All rights reserved.
|Title:||Molecular regulation of cardiac hypertrophy|
|Keywords:||cardiac, hypertrophy, molecular, signalling, transcription, NATRIURETIC-PEPTIDE RECEPTOR, LEUKEMIA INHIBITORY FACTOR, MYOSIN HEAVY-CHAIN, CHRONIC HEART-FAILURE, LEFT-VENTRICULAR MASS, GUANYLYL CYCLASE-A, PRESSURE-INDEPENDENT ENHANCEMENT, MYOCARDIAL GENE-EXPRESSION, MEF2 TRANSCRIPTION FACTOR, III HISTONE DEACETYLASE|
|UCL classification:||UCL > School of Life and Medical Sciences
UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science
UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Hatter Cardiovascular Institute
Archive Staff Only